Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc (REGN)

  • BCG Recommendation

Balfour Capital Group Researched Regeneron Pharmaceuticals Inc
 on March 14th, 2023.

Regeneron Pharmaceuticals (REGN) is a biotechnology company specializing in innovative treatments for various medical conditions, known for its advancements in research and drug development.

View Research
More Buy Recommendations

Post Recommendation Price Trend Chart

  • The chart's commencement marks the instance of our stock recommendation.
  • We have established a Buy recommendation at $765.76 on March 14th, 2023.
  • Our designated price target stands at $975.00.

Analysts Research

With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
BCG Logo (white)

Company Snapshot

Balfour Capital Group's precise and thorough research crafted by our team of analysts.

Our Research

View

Thomson Reuters on REGN

Thomson Reuters delivers global financial, legal, and business information to professionals.

Thomson Reuters Notes

View

Morgan Stanley on REGN

Morgan Stanley researches industries, offers insights to clients.

Morgan Stanley Notes

View

Argus Analysts on REGN

Argus Analysts Notes offers timely investment recommendations, insights.

Argus Analysts Notes

View

Argus Quantitive on REGN

Argus Quantitative analyzes energy, commodities, and finance with data analytics.

Argus Quantitive Report

View
Regeneron Pharmaceuticals Inc

2022 Q4 Earning Report

A Q4 report evaluates company financials for investors

Regeneron Pharmaceuticals Inc Report

View
Balfour Capital Group wants to clarify that our recommendation to Buy Regeneron Pharmaceuticals Inc (REGN) is based on thorough research conducted by our dedicated teams. We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance. However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.

*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
error: Content is protected !!